vs
Side-by-side financial comparison of AVANOS MEDICAL, INC. (AVNS) and CATHAY GENERAL BANCORP (CATY). Click either name above to swap in a different company.
CATHAY GENERAL BANCORP is the larger business by last-quarter revenue ($222.8M vs $180.9M, roughly 1.2× AVANOS MEDICAL, INC.). CATHAY GENERAL BANCORP runs the higher net margin — 653.4% vs -0.7%, a 654.1% gap on every dollar of revenue. On growth, CATHAY GENERAL BANCORP posted the faster year-over-year revenue change (19.5% vs 0.7%). CATHAY GENERAL BANCORP produced more free cash flow last quarter ($363.7M vs $21.3M). Over the past eight quarters, CATHAY GENERAL BANCORP's revenue compounded faster (12.8% CAGR vs 4.4%).
Avanos Medical, Inc. is a medical technology company making clinical medical devices. The company consists of two franchises – Pain Management and Chronic Care – that address reducing the use of opioids while helping patients recover faster and preventing infection.
Cathay General Bancorp is a U.S.-headquartered bank holding company that operates Cathay Bank, offering full-spectrum commercial and personal banking services. It primarily serves Asian American communities and small-to-medium enterprises across major U.S. states including California, New York and Texas, as well as select Asian markets, with products covering deposits, loans, and wealth management solutions.
AVNS vs CATY — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $180.9M | $222.8M |
| Net Profit | $-1.3M | $90.5M |
| Gross Margin | 47.5% | — |
| Operating Margin | 1.4% | 50.9% |
| Net Margin | -0.7% | 653.4% |
| Revenue YoY | 0.7% | 19.5% |
| Net Profit YoY | 99.7% | 12.9% |
| EPS (diluted) | $-0.02 | $1.33 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $180.9M | $222.8M | ||
| Q3 25 | $177.8M | $210.6M | ||
| Q2 25 | $175.0M | $196.6M | ||
| Q1 25 | $167.5M | $187.8M | ||
| Q4 24 | $179.6M | $186.5M | ||
| Q3 24 | $170.4M | $189.5M | ||
| Q2 24 | $171.7M | $178.5M | ||
| Q1 24 | $166.1M | $175.2M |
| Q4 25 | $-1.3M | $90.5M | ||
| Q3 25 | $-1.4M | $77.7M | ||
| Q2 25 | $-76.8M | $77.5M | ||
| Q1 25 | $6.6M | $69.5M | ||
| Q4 24 | $-397.3M | $80.2M | ||
| Q3 24 | $4.3M | $67.5M | ||
| Q2 24 | $1.8M | $66.8M | ||
| Q1 24 | $-900.0K | $71.4M |
| Q4 25 | 47.5% | — | ||
| Q3 25 | 48.4% | — | ||
| Q2 25 | 52.6% | — | ||
| Q1 25 | 53.6% | — | ||
| Q4 24 | 54.6% | — | ||
| Q3 24 | 54.5% | — | ||
| Q2 24 | 55.7% | — | ||
| Q1 24 | 57.1% | — |
| Q4 25 | 1.4% | 50.9% | ||
| Q3 25 | 0.1% | 44.5% | ||
| Q2 25 | -42.6% | 49.0% | ||
| Q1 25 | 6.1% | 46.1% | ||
| Q4 24 | -233.0% | 46.5% | ||
| Q3 24 | 7.0% | 41.2% | ||
| Q2 24 | 3.7% | 40.7% | ||
| Q1 24 | 2.4% | 45.7% |
| Q4 25 | -0.7% | 653.4% | ||
| Q3 25 | -0.8% | 36.9% | ||
| Q2 25 | -43.9% | 39.4% | ||
| Q1 25 | 3.9% | 37.0% | ||
| Q4 24 | -221.2% | 587.9% | ||
| Q3 24 | 2.5% | 35.6% | ||
| Q2 24 | 1.0% | 37.4% | ||
| Q1 24 | -0.5% | 40.8% |
| Q4 25 | $-0.02 | $1.33 | ||
| Q3 25 | $-0.03 | $1.13 | ||
| Q2 25 | $-1.66 | $1.10 | ||
| Q1 25 | $0.14 | $0.98 | ||
| Q4 24 | $-8.64 | $1.11 | ||
| Q3 24 | $0.09 | $0.94 | ||
| Q2 24 | $0.04 | $0.92 | ||
| Q1 24 | $-0.02 | $0.98 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.8M | — |
| Total DebtLower is stronger | $90.3M | $119.1M |
| Stockholders' EquityBook value | $778.2M | $2.9B |
| Total Assets | $1.1B | $24.2B |
| Debt / EquityLower = less leverage | 0.12× | 0.04× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $89.8M | — | ||
| Q3 25 | $70.5M | — | ||
| Q2 25 | $90.3M | — | ||
| Q1 25 | $97.0M | — | ||
| Q4 24 | $107.7M | — | ||
| Q3 24 | $89.0M | — | ||
| Q2 24 | $92.2M | — | ||
| Q1 24 | $75.8M | — |
| Q4 25 | $90.3M | $119.1M | ||
| Q3 25 | $93.4M | $119.1M | ||
| Q2 25 | $95.7M | $119.1M | ||
| Q1 25 | $98.0M | $119.1M | ||
| Q4 24 | $125.3M | $119.1M | ||
| Q3 24 | $152.6M | $119.1M | ||
| Q2 24 | $164.9M | $119.1M | ||
| Q1 24 | $167.2M | $119.1M |
| Q4 25 | $778.2M | $2.9B | ||
| Q3 25 | $778.0M | $2.9B | ||
| Q2 25 | $776.3M | $2.9B | ||
| Q1 25 | $839.4M | $2.9B | ||
| Q4 24 | $828.5M | $2.8B | ||
| Q3 24 | $1.2B | $2.8B | ||
| Q2 24 | $1.2B | $2.8B | ||
| Q1 24 | $1.2B | $2.8B |
| Q4 25 | $1.1B | $24.2B | ||
| Q3 25 | $1.1B | $24.1B | ||
| Q2 25 | $1.0B | $23.7B | ||
| Q1 25 | $1.1B | $23.2B | ||
| Q4 24 | $1.2B | $23.1B | ||
| Q3 24 | $1.7B | $23.3B | ||
| Q2 24 | $1.7B | $23.2B | ||
| Q1 24 | $1.7B | $23.4B |
| Q4 25 | 0.12× | 0.04× | ||
| Q3 25 | 0.12× | 0.04× | ||
| Q2 25 | 0.12× | 0.04× | ||
| Q1 25 | 0.12× | 0.04× | ||
| Q4 24 | 0.15× | 0.04× | ||
| Q3 24 | 0.12× | 0.04× | ||
| Q2 24 | 0.13× | 0.04× | ||
| Q1 24 | 0.14× | 0.04× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.2M | $368.6M |
| Free Cash FlowOCF − Capex | $21.3M | $363.7M |
| FCF MarginFCF / Revenue | 11.8% | 163.2% |
| Capex IntensityCapex / Revenue | 3.8% | 2.2% |
| Cash ConversionOCF / Net Profit | — | 4.07× |
| TTM Free Cash FlowTrailing 4 quarters | $43.1M | $672.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $28.2M | $368.6M | ||
| Q3 25 | $14.0M | $150.6M | ||
| Q2 25 | $6.8M | $64.0M | ||
| Q1 25 | $25.7M | $99.0M | ||
| Q4 24 | $57.9M | $329.2M | ||
| Q3 24 | $23.0M | $81.2M | ||
| Q2 24 | $27.8M | $72.9M | ||
| Q1 24 | $-8.0M | $88.2M |
| Q4 25 | $21.3M | $363.7M | ||
| Q3 25 | $7.0M | $150.1M | ||
| Q2 25 | $-4.2M | $62.7M | ||
| Q1 25 | $19.0M | $96.3M | ||
| Q4 24 | $53.1M | $325.5M | ||
| Q3 24 | $20.0M | $80.0M | ||
| Q2 24 | $21.9M | $72.4M | ||
| Q1 24 | $-12.1M | $87.3M |
| Q4 25 | 11.8% | 163.2% | ||
| Q3 25 | 3.9% | 71.3% | ||
| Q2 25 | -2.4% | 31.9% | ||
| Q1 25 | 11.3% | 51.2% | ||
| Q4 24 | 29.6% | 174.6% | ||
| Q3 24 | 11.7% | 42.2% | ||
| Q2 24 | 12.8% | 40.5% | ||
| Q1 24 | -7.3% | 49.8% |
| Q4 25 | 3.8% | 2.2% | ||
| Q3 25 | 3.9% | 0.2% | ||
| Q2 25 | 6.3% | 0.6% | ||
| Q1 25 | 4.0% | 1.4% | ||
| Q4 24 | 2.7% | 1.9% | ||
| Q3 24 | 1.8% | 0.6% | ||
| Q2 24 | 3.4% | 0.3% | ||
| Q1 24 | 2.5% | 0.5% |
| Q4 25 | — | 4.07× | ||
| Q3 25 | — | 1.94× | ||
| Q2 25 | — | 0.83× | ||
| Q1 25 | 3.89× | 1.42× | ||
| Q4 24 | — | 4.10× | ||
| Q3 24 | 5.35× | 1.20× | ||
| Q2 24 | 15.44× | 1.09× | ||
| Q1 24 | — | 1.23× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
CATY
Segment breakdown not available.
